论文部分内容阅读
目的:评价应用坦索罗辛治疗血压正常的前列腺增生症患者的临床疗效。方法:对61例前列腺增生症患者给予坦索罗辛0.2 mg/d,并依据治疗前后IPSS评分、QOL评分、剩余尿量、血压变化等情况进行疗效评估。结果:治疗6周后,与治疗前比较,血压变化差异无统计学意义(P>0.05),而IPSS评分、QOL评分及剩余尿量差异有统计学意义(P=0.000)。结论:坦索罗辛具有显效快、安全、经济、易接受的特点,可有效地降低尿道阻力。
Objective: To evaluate the clinical efficacy of tamsulosin in patients with benign prostatic hyperplasia. Methods: Twenty-six patients with benign prostatic hyperplasia were given tamsulosin 0.2 mg daily, and the curative effect was evaluated according to IPSS score, QOL score, residual urine volume and blood pressure before and after treatment. Results: After 6 weeks of treatment, there was no significant difference in blood pressure between before and after treatment (P> 0.05). There was significant difference between IPSS score, QOL score and residual urine volume (P = 0.000). Conclusion: Tamsulosin has the characteristics of fast, safe, economical and acceptable, which can effectively reduce urethral resistance.